|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
16
|
|
pubmed:dateCreated |
2007-8-16
|
|
pubmed:abstractText |
The mammalian target of rapamycin (mTOR) is a protein kinase that plays a key role in cellular growth and homeostasis. Because its regulation is frequently altered in tumors, mTOR is currently under investigation as a potential target for anticancer therapy. The purpose of our study was to determine the prognostic value of activated mTOR (p-mTOR) in patients with biliary tract adenocarcinoma (BTA), in order to strengthen the rationale for targeted therapy of BTA using mTOR inhibitors.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4795-9
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:17699857-Adenocarcinoma,
pubmed-meshheading:17699857-Adult,
pubmed-meshheading:17699857-Aged,
pubmed-meshheading:17699857-Biliary Tract Neoplasms,
pubmed-meshheading:17699857-Female,
pubmed-meshheading:17699857-Humans,
pubmed-meshheading:17699857-Immunohistochemistry,
pubmed-meshheading:17699857-Male,
pubmed-meshheading:17699857-Middle Aged,
pubmed-meshheading:17699857-Prognosis,
pubmed-meshheading:17699857-Protein Kinases,
pubmed-meshheading:17699857-Survival Rate,
pubmed-meshheading:17699857-TOR Serine-Threonine Kinases
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma.
|
|
pubmed:affiliation |
Department of Medicine I, Medical University of Vienna, Vienna, Austria.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
